News & Updates

Adding duloxetine to usual care does not appear to produce significant relief from chronic osteoarthritis pain as compared with usual care alone, a study has found.

Vaccines against SARS-CoV-2 has a safety profile that is similar in patients with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) and those with noninflammatory RMD (NI-RMD), according to a study. The vaccines are well tolerated with rare reports of I-RMD flare and serious adverse events.

Patients with gout consider flare duration, flare frequency, and pain severity when thinking about treatment efficacy over time, according to a study. Of these factors, shorter flare duration is deemed to be the most common indicator of successful treatment.

Use of opioid among adults with knee and/or hip osteoarthritis (OA) often leads to being familiar with the treatment and believing that the medication is beneficial and low-risk, reveals a recent study.

Patients with psoriatic arthritis exhibit reduced hand grip strength, with the deterioration of skill, coordination, and functionality of hand commensurate with the severity of psoriatic arthritis, a study has found.

Treatment with the monoclonal antibody targeting interleukin [IL]-23p19 guselkumab 100 mg, given either every 4 (Q4W) or 8 weeks (Q8W), is well tolerated in patients with psoriatic arthritis (PsA), with no new safety concerns through 1 year, according to pooled results of the DISCOVER-1 and DISCOVER-2 phase III trials.